Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CNR1 | P21554 | 9/20 | 0.50 |
| ▸ | CNR2 | P34972 | 7/20 | 0.50 |
| ▸ | MGLL | Q99685 | 1/20 | 0.50 |
| ▸ | THRB | P10828 | 3/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.49 |
| ▸ | MAPT | P10636 | 1/20 | 0.49 |
| ▸ | DNM1 | Q05193 | 1/20 | 0.49 |
| ▸ | THRA | P10827 | 1/20 | 0.46 |
| ▸ | PPARA | Q07869 | 1/20 | 0.45 |
| ▸ | HTR2A | P28223 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16012284 | 0.93 | THRB (0.49) | CNR1CNR2MGLLTHRBALDH1A1 | |
| SCHEMBL16012285 | 0.93 | THRB (0.49) | CNR1CNR2MGLLTHRBALDH1A1 | |
| SCHEMBL16012449 | 0.90 | THRB (0.50) | CNR1CNR2MGLLTHRBALDH1A1 | |
| SCHEMBL16012450 | 0.90 | THRB (0.50) | CNR1CNR2MGLLTHRBALDH1A1 | |
| SCHEMBL16013164 | 0.89 | CNR1 (0.44) | CNR1CNR2THRBTHRAPPARA | |
| SCHEMBL16013165 | 0.89 | CNR1 (0.44) | CNR1CNR2THRBTHRAPPARA | |
| SCHEMBL17685757 | 0.89 | MGLL (0.49) | CNR1CNR2MGLLTHRBALDH1A1 | |
| SCHEMBL16154807 | 0.89 | MGLL (0.49) | CNR1CNR2MGLLTHRBALDH1A1 | |
| SCHEMBL16013481 | 0.89 | MGLL (0.51) | CNR1CNR2MGLLTHRBALDH1A1 | |
| SCHEMBL21300565 | 0.89 | THRB (0.49) | CNR1CNR2MGLLTHRBALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20160106842-A1 | LIPIDS AND LIPID COMPOSITIONS FOR THE DELIVERY OF ACTIVE AGENTS | NOVARTIS INSTITUTES FOR BIOMEDICAL RESEARCH INC. | 2016-04-21 | — | — | US | claimed |
| US-12545636-B2 | Acyclic lipids and methods of use thereof | RENAGADE THERAPEUTICS MANAGEMENT INC. (US) | 2026-02-10 | — | — | US | disclosed |
| US-20250319190-A1 | APOE LIPOPROTEIN SYSTEMS | KISBEE THERAPEUTICS INC (US) | 2025-10-16 | — | — | US | disclosed |
| US-20250073164-A1 | IONIZABLE DISULFIDE LIPIDS AND LIPID NANOPARTICLES DERIVED THEREFROM | PROVIDENCE THERAPEUTICS HOLDINGS INC. (CA) | 2025-03-06 | — | — | US | disclosed |
| US-12215068-B2 | Constrained lipids and methods of use thereof | RENAGADE THERAPEUTICS MANAGEMENT INC. (US) | 2025-02-04 | — | — | US | disclosed |
| US-20240182412-A1 | CYCLIC LIPIDS AND METHODS OF USE THEREOF | RENAGADE THERAPEUTICS MAN INC (US) | 2024-06-06 | — | — | US | disclosed |
| US-20240067598-A1 | CONSTRAINED LIPIDS AND METHODS OF USE THEREOF | RENAGADE THERAPEUTICS MAN INC (US) | 2024-02-29 | — | — | US | disclosed |
| US-20230202966-A1 | ACYCLIC LIPIDS AND METHODS OF USE THEREOF | RENAGADE THERAPEUTICS MANAGEMENT INC. | 2023-06-29 | — | — | US | disclosed |
| EP-3608308-B1 | LIPIDS AND LIPID COMPOSITIONS FOR THE DELIVERY OF ACTIVE AGENTS | NOVARTIS AG (CH) | 2021-07-21 | — | — | EP | disclosed |
| US-10792361-B2 | Lipids and lipid compositions for the delivery of active agents | NOVARTIS AG (CH) | 2020-10-06 | — | — | US | disclosed |
| EP-3608308-A1 | LIPIDS AND LIPID COMPOSITIONS FOR THE DELIVERY OF ACTIVE AGENTS | Novartis AG (CH) | 2020-02-12 | — | — | EP | disclosed |
| EP-2964608-B1 | LIPIDS AND LIPID COMPOSITIONS FOR THE DELIVERY OF ACTIVE AGENTS | NOVARTIS AG (CH) | 2019-08-28 | — | — | EP | disclosed |
| US-10124065-B2 | Lipids and lipid compositions for the delivery of active agents | NOVARTIS AG (CH) | 2018-11-13 | — | — | US | disclosed |
| US-20160106842-A1 | LIPIDS AND LIPID COMPOSITIONS FOR THE DELIVERY OF ACTIVE AGENTS | NOVARTIS INSTITUTES FOR BIOMEDICAL RESEARCH INC. | 2016-04-21 | — | — | US | disclosed |
| US-20160106842-A1 | LIPIDS AND LIPID COMPOSITIONS FOR THE DELIVERY OF ACTIVE AGENTS | NOVARTIS INSTITUTES FOR BIOMEDICAL RESEARCH INC. | 2016-04-21 | — | — | US | disclosed |
| US-20160106842-A1 | LIPIDS AND LIPID COMPOSITIONS FOR THE DELIVERY OF ACTIVE AGENTS | NOVARTIS INSTITUTES FOR BIOMEDICAL RESEARCH INC. | 2016-04-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250319190-A1 | APOE LIPOPROTEIN SYSTEMS | APOB, APOL1, LDLR | CNR1 3876/4885CNR2 3684/4885MGLL 19/4885 |
| US-20250073164-A1 | IONIZABLE DISULFIDE LIPIDS AND LIPID NANOPARTICLES DERIVED THEREFROM | SGMS1, SGMS2, ABCB4 | CNR1 4587/4885CNR2 4337/4885MGLL 301/4885 |
| US-12545636-B2 | Acyclic lipids and methods of use thereof | PLTP, LNPEP, PCTP | CNR1 3071/4885CNR2 2980/4885MGLL 28/4885 |
| US-10124065-B2 | Lipids and lipid compositions for the delivery of active agents | LIPA, LPAR1, LPAR4 | CNR1 1158/4885CNR2 2230/4885MGLL 28/4885 |
| US-12215068-B2 | Constrained lipids and methods of use thereof | SGMS1, SGMS2, LNPEP | CNR1 3077/4885CNR2 2889/4885MGLL 25/4885 |
| US-20240182412-A1 | CYCLIC LIPIDS AND METHODS OF USE THEREOF | SGMS1, SGMS2, LNPEP | CNR1 3959/4885CNR2 3947/4885MGLL 31/4885 |
| US-20240067598-A1 | CONSTRAINED LIPIDS AND METHODS OF USE THEREOF | SGMS1, SGMS2, LNPEP | CNR1 3077/4885CNR2 2889/4885MGLL 25/4885 |
| US-20160106842-A1 | LIPIDS AND LIPID COMPOSITIONS FOR THE DELIVERY OF ACTIVE AGENTS | LIPA, LPAR1, LPAR4 | CNR1 1158/4885CNR2 2230/4885MGLL 28/4885 |
| US-10792361-B2 | Lipids and lipid compositions for the delivery of active agents | LIPA, LPAR1, LPAR4 | CNR1 1158/4885CNR2 2230/4885MGLL 28/4885 |
| US-20230202966-A1 | ACYCLIC LIPIDS AND METHODS OF USE THEREOF | SGMS1, SGMS2, ABHD16A | CNR1 3494/4885CNR2 3520/4885MGLL 45/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.